Vidin Eric, Garbin Olivier, Rodriguez Brice, Favre Romain, Bettahar-Lebugle Karima
Service de Gynécologie, SIHCUS-CMCO, 67300 Schiltigheim, France.
Contraception. 2007 Jul;76(1):35-9. doi: 10.1016/j.contraception.2007.03.012. Epub 2007 May 24.
We describe removal procedures for etonogestrel contraceptive implants in the operating theater. In addition, we discuss the management of removal of contraceptive implants that are difficult to palpate or are impalpable.
We conducted a retrospective single-center case series analysis of Implanon removals conducted at a university hospital between January 2002 and April 2005.
We analyzed case notes for 28 patients who had their contraceptive implant removed in the operating theater.
Intermenstrual bleeding was the principal reason for removal (52.4%). Ten patients already had one attempted removal of their implant. Preoperative ultrasound localized the implant in all cases. Half of the removals were done under local anesthetic, with three cases progressing to general anesthesia (11%). Thirty percent of the implants had migrated from their initial implantation, 37% were in intramuscular tissue and 11% were in the humeral neurovascular sheath. The only postoperative complications were one small seroma and transient paresthesia in the territory of the ulnar nerve. The implant was not found in one case.
The removal of an implant that is not palpable or difficult to palpate should take place in the operating theater following localization by ultrasound. Patients must be fully informed about the procedure, including its complications and the risk for failure.
我们描述了在手术室取出依托孕烯避孕植入剂的操作程序。此外,我们还讨论了难以触及或无法触及的避孕植入剂取出的管理方法。
我们对2002年1月至2005年4月在一家大学医院进行的依伴侬取出术进行了回顾性单中心病例系列分析。
我们分析了28例在手术室取出避孕植入剂患者的病历。
月经间期出血是取出植入剂的主要原因(52.4%)。10例患者此前已尝试过一次取出植入剂。术前超声在所有病例中均定位到了植入剂。一半的取出手术在局部麻醉下进行,3例进展为全身麻醉(11%)。30%的植入剂已从初始植入位置移位,37%位于肌肉组织中,11%位于肱骨神经血管鞘内。术后仅出现1例小血清肿和尺神经区域短暂感觉异常。有1例未找到植入剂。
对于无法触及或难以触及的植入剂,应在超声定位后在手术室进行取出。必须让患者充分了解该操作,包括其并发症和失败风险。